Source: Investing Published 07/29/2024, 10:29
On Monday, Morgan Stanley downgraded Evotec AG (EVT:GR) (NASDAQ: EVO) stock, moving the rating from Overweight to Equal Weight. The firm also revised its target price on the stock to €12.00 from €28.00 previously.
The revision comes as Evotec’s narrative shifts from a focus on innovation and technological prowess to a renewed focus on its core contract research organization (CRO) business, with the goal of profitable growth.
The Morgan Stanley analyst noted that Evotec has restructured its reporting segments into two distinct areas: the “Combined Research and Development” segment, which includes the CRO business including transactional and discovery services, and “Only – Evotec Biologics”, which operates the contract development and manufacturing organization (CDMO) business. This streamlining effort is seen as a positive step to help investors better understand the company’s underlying revenue growth and profitability drivers.
The reassessment by Morgan Stanley comes at a pivotal time when Evotec’s growth and profitability margins are facing challenges. The restructuring is intended to provide a clearer picture of the company’s operations, which could help assess the company’s fundamentals, which have become more complex to analyze in recent times.
The financial institution’s comment highlights a strategic pivot for Evotec, as the company moves from focusing on its innovative approaches and AI-driven R&D to focusing on the core aspects of its R&D business. This move is intended to pave the way for Evotec to weather a period of growth and tighter margins.
In other recent news, Evotec has seen significant changes to its financial and strategic landscape. The company reported a mixed performance in the first quarter of 2024, with revenues down to €208.8 million and a significant decline in adjusted EBITDA due to a 23% decline in shared R&D revenue. However, the discovery book saw a 70% increase, and Just Evotec Biologics, a subsidiary of Evotec, saw revenue growth of nearly 400% and achieved breakeven EBITDA.
Morgan Stanley downgraded Evotec from overweight to equal weight and lowered its price target to €12.00, reflecting the current pressure on the company’s growth and margins. The company’s restructuring, which splits the business into “Joint R&D” and “Just – Evotec Biologics,” is seen as a positive step towards clarity for investors.
In contrast, TD Cowen maintained its buy rating on Evotec shares, following a visit to the company’s GMP J.POD facility in Redmond, Washington. The facility is part of Evotec’s strategy to streamline biologics production.
Evotec is also divesting its gene therapy business to focus on core strengths and expects a rebound in the second half of 2024. The company is executing cost optimization and smart partnership strategies to navigate the current market.
Despite the current challenges, Evotec maintains its guidance for mid-double-digit EBITDA growth for 2024 and expects the BIO-SECURE Act to have a positive impact going forward. These are among the latest developments in Evotec’s strategic and financial landscape.
InvestingPro Insights
As Evotec AG (EVT:GR) (NASDAQ:EVO) (NASDAQ:EVO) faces a pivotal shift in its business strategy, real-time data from InvestingPro provides further context to the company’s current financial position. With a market cap of around $1.67 billion, Evotec’s valuation reflects the challenges identified by Morgan Stanley. The company’s P/E ratio is -16.58, indicating that investors are currently facing losses, and this is further confirmed by the trailing twelve-month adjusted P/E ratio as of Q1 2024 at -36.77, indicating that the market is not expecting profitability in the near term.
InvestingPro’s advice highlights that Evotec is operating with a moderate level of debt, which could impact its financial flexibility given the strategic pivot. Additionally, the company’s high valuation multiple to EBITDA could indicate that the stock is optimistically priced relative to its EBITDA. With no dividends paid to shareholders, investment returns will be dependent solely on the stock price appreciation, which has been under pressure as evidenced by the 1-year total price return of -62.15%.
For investors looking to dig deeper into Evotec’s financials and future prospects, InvestingPro offers more insights and advice. By using coupon code PRONEWS24, readers can get up to 10% off an annual Pro subscription and an annual or semi-annual Pro+ subscription, giving them access to 4 additional tips from Inv esti ngPro that can help them make investment decisions.
This article was translated with the help of an AI program after being reviewed by an editor. For more details, please refer to the terms and conditions of the article
EVO: Bull or Bear Market?
Don’t miss the next big opportunity! Stay ahead of the curve with ProPicks as you get 6 model portfolios powered by AI picks of the best performing stocks this year.
In 2024 alone, ProPicks’ AI identified 2 stocks that jumped more than 150%, 4 additional stocks that jumped more than 30%, and 3 more stocks that rose more than 25%. That’s a solid track record.
With portfolios designed to track Dow Jones, S&P, technology and mid-cap stocks, you can explore different wealth-building strategies.
So if EVO is on your watchlist, it might make a lot of sense to see if it makes it onto ProPicks.
